Ulipristal
- Atc Codes:G03AD02
- CAS Codes:126784-99-4
- PHARMGKB ID:126784-99-4
Table of contents
- Brand Names
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Genes that may be involved
- Substrate of
- Drug Interactions
- Nutrition/Nutraceutical Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
Europe
Austria: Ellaone; Belgium: Ellaone; Bulgaria: Ellaone; Denmark: Ellaone; Estonia: Ellaone; Finland: Ellaone; France: Ellaone; Germany: Ellaone; Greece: Ellaone; Hungary: Ellaone; Ireland: Ellaone; Latvia: Ellaone; Lithuania: Ellaone; Luxembourg: Ellaone; Malta: Ellaone; Netherlands: Ellaone; Poland: Ellaone; Portugal: Ellaone; Romania: Ellaone; Slovakia: Ellaone; Slovenia: Ellaone; Spain: Ellaone; Sweden: Ellaone; UK: Ellaone.
North America
USA: Ella.
Drug combinations
Chemistry
Ulipristal Acetate: C~30~H~37~NO~4~. Mw: 475.6. [17α acetoxy-11β-(4-N,N-dimethylaminophenyl)-19-norpregna-4,9-diene-3,20-dione]. CAS-126784-99-4.
Pharmacologic Category
Hormones and Synthetic Substitutes; Contraceptives; Synthetic Progesterone Agonist/Antagonist, Emergency Contraceptive. (ATC-Code: G03AD02).
Mechanism of action
When taken immediately before ovulation is to occur, postpones follicular rupture. The likely primary mechanism of action of ulipristal acetate for emergency contraception is therefore inhibition or delay of ovulation; however, alterations to the endometrium that may affect implantation may also contribute to efficacy. Ulipristal acetate is a selective progesterone receptor modulator with antagonistic and partial agonistic effects (a progesterone agonist/antagonist) at the progesterone receptor. It binds the human progesterone receptor and prevents progesterone from occupying its receptor.
Therapeutic use
Indicated for prevention of pregnancy following unprotected intercourse or a known or suspected contraceptive failure. Not intended for routine use as a contraceptive.
Pregnancy and lactiation implications
Not recommended for use by breastfeeding women. Not intended for use in premenarcheal or postmenopausal women.
Unlabeled use
Contraindications
Known or suspected pregnancy.
Warnings and precautions
Not indicated for termination of an existing pregnancy. Women who become pregnant or complain of lower abdominal pain after taking ulipristal should be evaluated for ectopic pregnancy. May alter the next expected menses. Repeated use within the same menstrual cycle is not recommended. After its use, a reliable barrier method of contraception should be used with subsequent acts of intercourse that occur in that same menstrual cycle. Does not protect against HIV infection (AIDS) or other sexually transmitted infections (STIs). The tablet must be taken as soon as possible within 5 days (120 hours) after unprotected sex or after a birth control failure.